# TSH suppression attenuates the early efficacy of zoledronic acid in osteoporosis

## TL;DR

TSH suppression reduces the early effectiveness of zoledronic acid for treating osteoporosis in thyroid cancer patients.

## Contribution

This study shows that TSH suppression therapy diminishes the early skeletal response to zoledronic acid in postoperative thyroid cancer patients with osteoporosis.

## Key findings

- TSH suppression was linked to less bone mineral density improvement at 9 months.
- Bone turnover markers remained elevated in the TSH suppression group.
- The effect was more pronounced in postmenopausal women.

## Abstract

TSH suppression was associated with an attenuated early skeletal response to zoledronic acid in postoperative DTC patients with osteoporosis.

This prospective study aimed to evaluate the impact of TSH suppression therapy on the early skeletal efficacy of zoledronic acid in patients with differentiated thyroid cancer (DTC), and to explore whether this response differs across subgroups.

Patients were divided into two groups: the osteoporosis with TSH suppression group (TSH + OP, n = 42) and the osteoporosis without TSH suppression group (TSH − OP, n = 67). Both groups received a single infusion of zoledronic acid (5 mg) along with daily calcium and calcitriol supplementation. Primary analyses compared changes in bone mineral density (BMD) and bone turnover markers(BTMs) at 6 and 9 months post-treatment. After propensity score matching (PSM), 36 patients from each group were included in the primary analyses. Exploratory subgroup analyses were conducted according to age and sex.

After PSM, the TSH + OP group showed significantly less BMD improvement compared to the TSH − OP group. At 9 months, the intergroup differences in BMD change were -7.08 mg/cm2 (lumbar, P = 0.02), -12.03 mg/cm2 (left hip, P < 0.001) and -6.12 mg/cm2 (femoral neck, P < 0.001). BTMs (PINP and β-CTX) remained higher in the TSH + OP group at all time points (all P < 0.01). Subgroup analyses suggested that these differences were primarily observed in postmenopausal patients.

TSH suppression therapy was associated with an attenuated early skeletal response to zoledronic acid in postoperative DTC patients with osteoporosis, with this attenuation being more pronounced at the hip and femoral neck. Exploratory subgroup analyses suggested that this attenuation was primarily observed in postmenopausal women. In patients undergoing TSH suppression, serum PINP and β-CTX are useful monitoring biomarkers.